Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Adaptimmune and GSK entered a strategic collaboration for up to five programs including the lead NY-ESO TCR program, with cash payments of approximately…
GSK upsizes its bet on Adaptimmune, accelerating NY-ESO-1 SPEAR T-cell therapy toward registration trials in synovial sarcoma — raising potential program value…
GSK exercised its exclusive option for the NY-ESO SPEAR T-cell program ahead of schedule, paying Adaptimmune ~£48M; program later returned to Adaptimmune in…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK and Adaptimmune signed a strategic collaboration covering up to five engineered TCR cell-therapy programs led by NY-ESO-1, with potential payments up to $350M over seven years. The deal validated Adaptimmune's SPEAR platform and was the foundation for letetresgene autoleucel; ultimately wound down by GSK in 2024.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Adaptimmune Therapeutics plc (this deal) | 2014 | $350M | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2014 deals · GlaxoSmithKline plc deals · Hematology deals